REGN
Price
$694.99
Change
+$13.27 (+1.95%)
Updated
Nov 13 closing price
Capitalization
73.04B
77 days until earnings call
Intraday BUY SELL Signals
SMMT
Price
$18.26
Change
-$0.57 (-3.03%)
Updated
Nov 13 closing price
Capitalization
13.59B
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REGN vs SMMT

Header iconREGN vs SMMT Comparison
Open Charts REGN vs SMMTBanner chart's image
Regeneron Pharmaceuticals
Price$694.99
Change+$13.27 (+1.95%)
Volume$1.51M
Capitalization73.04B
Summit Therapeutics
Price$18.26
Change-$0.57 (-3.03%)
Volume$1.84M
Capitalization13.59B
REGN vs SMMT Comparison Chart in %
REGN
Daily Signal:
Gain/Loss:
SMMT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
REGN vs. SMMT commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a StrongBuy and SMMT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (REGN: $694.99 vs. SMMT: $18.83)
Brand notoriety: REGN: Notable vs. SMMT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 141% vs. SMMT: 45%
Market capitalization -- REGN: $73.04B vs. SMMT: $13.59B
REGN [@Biotechnology] is valued at $73.04B. SMMT’s [@Biotechnology] market capitalization is $13.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 1 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • REGN’s FA Score: 1 green, 4 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than SMMT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 6 TA indicator(s) are bullish while SMMT’s TA Score has 5 bullish TA indicator(s).

  • REGN’s TA Score: 6 bullish, 4 bearish.
  • SMMT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, REGN is a better buy in the short-term than SMMT.

Price Growth

REGN (@Biotechnology) experienced а +7.44% price change this week, while SMMT (@Biotechnology) price change was +4.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

REGN is expected to report earnings on Jan 30, 2026.

SMMT is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($73B) has a higher market cap than SMMT($13.6B). SMMT has higher P/E ratio than REGN: SMMT (26.36) vs REGN (16.66). SMMT YTD gains are higher at: 5.520 vs. REGN (-2.016). REGN has higher annual earnings (EBITDA): 5.42B vs. SMMT (-743.48M). REGN has more cash in the bank: 7.47B vs. SMMT (298M). SMMT has less debt than REGN: SMMT (5.55M) vs REGN (2.71B). REGN has higher revenues than SMMT: REGN (14.2B) vs SMMT (0).
REGNSMMTREGN / SMMT
Capitalization73B13.6B537%
EBITDA5.42B-743.48M-729%
Gain YTD-2.0165.520-37%
P/E Ratio16.6626.3663%
Revenue14.2B0-
Total Cash7.47B298M2,507%
Total Debt2.71B5.55M48,712%
FUNDAMENTALS RATINGS
REGN vs SMMT: Fundamental Ratings
REGN
SMMT
OUTLOOK RATING
1..100
2166
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
8852
SMR RATING
1..100
54100
PRICE GROWTH RATING
1..100
4483
P/E GROWTH RATING
1..100
677
SEASONALITY SCORE
1..100
44n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for SMMT (94). This means that REGN’s stock grew significantly faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (52) in the Biotechnology industry is somewhat better than the same rating for REGN (88). This means that SMMT’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for SMMT (100). This means that REGN’s stock grew somewhat faster than SMMT’s over the last 12 months.

REGN's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for SMMT (83). This means that REGN’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's P/E Growth Rating (7) in the Biotechnology industry is somewhat better than the same rating for REGN (67). This means that SMMT’s stock grew somewhat faster than REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNSMMT
RSI
ODDS (%)
Bearish Trend 2 days ago
44%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
54%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
52%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
43%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
REGN
Daily Signal:
Gain/Loss:
SMMT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPXN74.261.46
+2.01%
ProShares S&P 500® ex-Financials
LCTU74.500.12
+0.16%
BlackRock US Carbon Transition Rdnss ETF
OBIL50.19N/A
N/A
F/m US Treasury 12 Month Bill ETF
HAPY24.53N/A
N/A
Harbor Human Capital Factor Unconstrained ETF
RNTY49.97-0.31
-0.61%
Yieldmax Target 12 Real Estate Option Income ETF

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
-1.72%
BCDA - SMMT
70%
Closely correlated
-2.26%
TIL - SMMT
52%
Loosely correlated
-4.83%
BNTX - SMMT
51%
Loosely correlated
+2.81%
IDYA - SMMT
42%
Loosely correlated
-0.19%
MGNX - SMMT
42%
Loosely correlated
-3.29%
More